Well its about time the new board gave us all an update on what they have done since taking over. they should be very close now to signing up the deals that they stated were at an advanced stage in their last report. The company needs build confidence to the market based on factual info in rolling out the product.
We need updates and contracts on the roll out to Europe, China, and FDA Approval timeline. I do believe that they will turn this around soon, but there is no doubt that the company was damaged by the previous management who know doubt made a killing in selling of their shares after departing. Karma will ensure there future.
We shareholders will benefit from the team now building the company, the product is real and will be in demand when the marketing expertise is delivered.
ISN Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
